Compare Gilead Sciences, Inc. (GILD) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs VanEck Rare Earth/Strategic Metals — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while VanEck Rare Earth/Strategic Metals trades at $77.99. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while VanEck Rare Earth/Strategic Metals pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| GILD | REMX | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $109.53 |
52-Week Low | $110.56 | $56.60 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
